|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global regional and national cancer incidence mortality years of
life lost years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pathmanathan N and Balleine RL: Ki67 and
proliferation in breast cancer. J Clin Pathol. 66:512–516. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dong LF and Neuzil J: Mitochondria in
cancer: Why mitochondria are a good target for cancer therapy. Prog
Mol Biol Transl Sci. 127:211–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shoshan-Barmatz V, Krelin Y,
Shteinfer-Kuzmine A and Arif T: Voltage-dependent anion channel 1
as an emerging drug target for novel anti-cancer therapeutics.
Front Oncol. 7:1542017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shoshan-Barmatz V, De Pinto V,
Zweckstetter M, Raviv Z, Keinan N and Arbel N: VDAC, a
multi-functional mitochondrial protein regulating cell life and
death. Mol Aspects Med. 31:227–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lemasters JJ: Evolution of
voltage-dependent anion channel function: From molecular sieve to
governator to actuator of ferroptosis. Front Oncol. 7:3032017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shoshan-Barmatz V, Nahon-Crystal E,
Shteinfer-Kuzmine A and Gupta R: VDAC1, mitochondrial dysfunction,
and alzheimer's disease. Pharmacol Res. 131:87–101. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pittala S, Krelin Y and Shoshan-Barmatz V:
Targeting liver cancer and associated pathologies in mice with a
mitochondrial VDAC1-Based peptide. Neoplasia. 20:594–609. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang G, Jiang G, Wang C, Zhong K, Zhang
J, Xue Q, Li X, Jin H and Li B: Decreased expression of
microRNA-320a promotes proliferation and invasion of non-small cell
lung cancer cells by increasing VDAC1 expression. Oncotarget.
7:49470–49480. 2016.PubMed/NCBI
|
|
10
|
Zhang C, Ding W, Liu Y, Hu Z, Zhu D, Wang
X, Yu L, Wang L, Shen H, Zhang W, et al: Proteomics-based
identification of VDAC1 as a tumor promoter in cervical carcinoma.
Oncotarget. 7:52317–52328. 2016.PubMed/NCBI
|
|
11
|
Magri A, Reina S and De Pinto V: VDAC1 as
pharmacological target in cancer and neurodegeneration: Focus on
its role in apoptosis. Front Chem. 6:1082018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reina S and De Pinto V: Anti-cancer
compounds targeted to VDAC: Potential and perspectives. Curr Med
Chem. 24:4447–4469. 2017.PubMed/NCBI
|
|
13
|
Sahni JM and Keri RA: Targeting
bromodomain and extraterminal proteins in breast cancer. Pharmacol
Res. 129:156–176. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dai X, Gan W, Li X, Wang S, Zhang W, Huang
L, Liu S, Zhong Q, Guo J, Zhang J, et al: Prostate
cancer-associated SPOP mutations confer resistance to BET
inhibitors through stabilization of BRD4. Nat Med. 23:1063–1071.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Decker TM, Kluge M, Krebs S, Shah N, Blum
H, Friedel CC and Eick D: Transcriptome analysis of
dominant-negative Brd4 mutants identifies Brd4-specific target
genes of small molecule inhibitor JQ1. Sci Rep. 7:16842017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin X, Yan Y, Wang D, Ding D, Ma T, Ye Z,
Jimenez R, Wang L, Wu H and Huang H: DUB3 Promotes BET Inhibitor
resistance and cancer progression by deubiquitinating BRD4. Mol
Cell. 71:592–605.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Delmore JE, Issa GC, Lemieux ME, Rahl PB,
Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et
al: BET bromodomain inhibition as a therapeutic strategy to target
c-Myc. Cell. 146:904–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye
Z, Wang S, Pan CW, Zhu Y, Yan Y, et al: Intrinsic BET inhibitor
resistance in SPOP-mutated prostate cancer is mediated by BET
protein stabilization and AKT-mTORC1 activation. Nat Med.
23:1055–1062. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arif T, Vasilkovsky L, Refaely Y, Konson A
and Shoshan-Barmatz V: Silencing VDAC1 Expression by siRNA Inhibits
cancer cell proliferation and tumor growth in vivo. Mol Ther
Nucleic Acids. 3:e1592014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Freitas S, Martins R, Costa M, Leão PN,
Vitorino R, Vasconcelos V and Urbatzka R: Hierridin B isolated from
a marine cyanobacterium alters VDAC1, mitochondrial activity, and
cell cycle genes on HT-29 Colon adenocarcinoma cells. Mar Drugs.
14(pii): E1582016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maimaiti A, Aili A, Kuerban H and Li X:
VDAC1 Mediated anticancer activity of gallic acid in human lung
adenocarcinoma A549 cells. Anticancer Agents Med Chem. 18:255–262.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thinnes FP: Neuroendocrine differentiation
of LNCaP cells suggests: VDAC in the cell membrane is involved in
the extrinsic apoptotic pathway. Mol Genet Metab. 97:241–243. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shoshan-Barmatz V, Israelson A, Brdiczka D
and Sheu SS: The voltage-dependent anion channel (VDAC): Function
in intracellular signalling, cell life and cell death. Curr Pharm
Des. 12:2249–2270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shoshan-Barmatz V and Mizrachi D: VDAC1:
From structure to cancer therapy. Front Oncol. 2:1642012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seyfried TN and Shelton LM: Cancer as a
metabolic disease. Nutr Metab (Lond). 7:72010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weisthal S, Keinan N, Ben-Hail D, Arif T
and Shoshan-Barmatz V: Ca(2+)-mediated regulation of VDAC1
expression levels is associated with cell death induction. Biochim
Biophys Acta. 1843:2270–2281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Castagna A, Antonioli P, Astner H, Hamdan
M, Righetti SC, Perego P, Zunino F and Righetti PG: A proteomic
approach to cisplatin resistance in the cervix squamous cell
carcinoma cell line A431. Proteomics. 4:3246–3267. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jung JY, Han CR, Jeong YJ, Kim HJ, Lim HS,
Lee KH, Park HO, Oh WM, Kim SH and Kim WJ: Epigallocatechin gallate
inhibits nitric oxide-induced apoptosis in rat PC12 cells. Neurosci
Lett. 411:222–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nawarak J, Huang-Liu R, Kao SH, Liao HH,
Sinchaikul S, Chen ST and Cheng SL: Proteomics analysis of A375
human malignant melanoma cells in response to arbutin treatment.
Biochim Biophys Acta. 1794:159–167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leone A, Roca MS, Ciardiello C,
Terranova-Barberio M, Vitagliano C, Ciliberto G, Mancini R, Di
Gennaro E, Bruzzese F and Budillon A: Vorinostat synergizes with
EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation
of the major mitochondrial porin VDAC1 and modulation of the
c-Myc-NRF2-KEAP1 pathway. Free Radic Biol Med. 89:287–299. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bhat TA, Kumar S, Chaudhary AK, Yadav N
and Chandra D: Restoration of mitochondria function as a target for
cancer therapy. Drug Discov Today. 20:635–643. 2015. View Article : Google Scholar : PubMed/NCBI
|
